Hims & Hers Health Inc began offering a generic version of semaglutide in Canada on Thursday. The telehealth provider is leveraging the patent expiry of Novo Nordisk A/S-B to launch its first international GLP-1 weight-loss offering. This expansion allows the firm to capture market share in a high-demand category with pricing 25% lower than the minimum cost of branded alternatives.
Hims and Hers Launches Generic Semaglutide in Canada
Hims and Hers Health has launched generic semaglutide in Canada via its telehealth platform. The Apotex-made drug will start at 149 Canadian dollars per month.
Xurve View
Insights:
Xurve View








